協鑫科技(03800.HK)折讓8.7%配股 淨籌53.92億元
協鑫科技(03800.HK)公佈,配售47.36億股新股,佔擴大後股本約14.26%,每股作價1.15元,較昨日(15日)收市價1.26元折讓約8.73%。
公司預期,配售事項所得款項淨額約53.92億元,擬將65%主要用於供給側改革的資金儲備,推進多晶硅產能結構性調整;強化第二曲線,以全球第一的硅烷氣產能和產量,完成海外替代,在半導體集成電路對電子特氣需求的提升、TOPCon電池向太陽能BC電池轉型對硅烷需求的放量,鋰電行業固態、半固態電池對硅烷的應用需求以及顯示面板對硅烷氣品質的高要求的多重背景下,以硅烷氣打造協鑫新增長極;優化公司資本結構。餘下35%用於一般營運資金用途及償還現有貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.